英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
gesturist查看　gesturist　在百度字典中的解释百度英翻中〔查看〕
gesturist查看　gesturist　在Google字典中的解释Google英翻中〔查看〕
gesturist查看　gesturist　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2 . . .
    Adjuvant abemaciclib reduces the risk of recurrence The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine
  • Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor . . .
    Patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–), node-positive early breast cancer (EBC) are at high risk of recurrence (up to 30% at 5 years 1) and need intensification of treatment Two years of adjuvant abemaciclib in combination with endocrine therapy (ET) is an internationally approved standard of care with National
  • FDA expands early breast cancer indication for abemaciclib with . . .
    Abemaciclib was previously approved for the above high-risk population with the additional requirement of having a Ki-67 score ≥20% Today’s approval removes the Ki-67 testing requirement
  • NCCN Guidelines | Verzenio (abemaciclib) - Eli Lilly and Company
    VERZENIO (abemaciclib) is a kinase inhibitor indicated 1: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence
  • Practical Guidance on Abemaciclib in Combination with Adjuvant . . .
    The addition of 2 years of abemaciclib to adjuvant ET for HR-positive, HER2-negative high-risk early-stage breast cancer has significantly improved IDFS and DRFS, as demonstrated by the results of the monarchE trial, although no overall survival benefit has been demonstrated thus far 50 In 2023, abemaciclib was the only oral CDK4 6 inhibitor
  • Abemaciclib May Be Option for Early-Stage Breast Cancer
    However, several breast cancer experts noted that it’s not yet clear how abemaciclib would be used to treat early-stage breast cancer In part, that’s because in two other clinical trials involving a similar group of patients, adding the CDK4 6 inhibitor palbociclib to adjuvant hormone therapy failed to improve invasive disease-free survival
  • Abemaciclib as adjuvant treatment for high-risk early breast cancer
    The efficacy and safety of abemaciclib were evaluated in a randomized, open-label, and multicenter phase III study A total of 5637 patients diagnosed with early breast cancer with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive, and high risk of recurrence were included
  • Abemaciclib: A Review in Early Breast Cancer with a High Risk of . . .
    Abemaciclib [Verzenio ® (USA) or Verzenios ® (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), node-positive, early breast cancer with a high risk of recurrence In a phase III trial, abemaciclib plus endocrine
  • Adding abemaciclib to treatment leads to longer time without . . . - LBBC
    Update: Abemaciclib (Verzenio) was FDA approved for early-stage, high-risk breast cancer in October 2021 This article provides context about the FDA approval The monarchE study found that adding the CDK 4 6 inhibitor abemacicilib (Verzenio) to hormonal therapy helped people with early-stage, hormone receptor-positive breast cancer who had a high risk of recurrence go longer without cancer
  • FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk . . .
    PURPOSE The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥ 20%





中文字典-英文字典  2005-2009